Human erythroid cells produced ex vivo at large scale differentiate into red blood cells in vivo.
Neildez-Nguyen TM. (1), Wajcman H. (2), Marden MC. (3), Bensidhoum M. (4), Moncollin V (1), Giarratana MC. (1), Kobari L.(1), Thierry D.(4), Douay L. (1,5)
Nature Biotechnology 20(5):467-72, 2002
(1) Institut National de la Sante et de la Recherche Medicale (INSERM) U417, Hôpital Saint-Antoine, Paris, France
(2) INSERM U468, Hôpital Henri Mondor, Creteil, France
(3) INSERM U473, Hôpital de Bicêtre, Kremlin-Bicêtre, France
(4) IRSN/DPHD/SARAM/LRH, Fontenay-aux-Roses, France
(5) Service d'Hématologie Biologique, Hôpital Armand Trousseau, Paris, France
New sources of red blood cells (RBCs) would improve the transfusion capacity of blood centers. Our objective was to generate cells for transfusion by inducing a massive proliferation of hematopoietic stem and progenitor cells, followed by terminal erythroid differentiation. We describe here a procedure for amplifying hematopoietic stem cells (HSCs) from human cord blood (CB) by the sequential application of specific combinations of growth factors in a serum-free culture medium. The procedure allowed the ex vivo expansion of CD34(+) progenitor and stem cells into a pure erythroid precursor population. When injected into nonobese diabetic, severe combined immunodeficient (NOD/SCID) mice, the erythroid cells were capable of proliferation and terminal differentiation into mature enucleated RBCs. The approach may eventually be useful in clinical transfusion applications.